These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2014584)

  • 1. [Systemic chemotherapy of urothelial carcinoma].
    Wolff J; Jakse G
    Urologe A; 1991 Jan; 30(1):25-32. PubMed ID: 2014584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chemotherapy of bladder carcinoma. Current status and trends].
    Block T
    Urologe A; 1994 Nov; 33(6):557-67. PubMed ID: 7817457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
    Stöckle M; Meyenburg W; Wellek S; Voges GE; Rossmann M; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    J Urol; 1995 Jan; 153(1):47-52. PubMed ID: 7966789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and results.
    Scher HI
    Urol Clin North Am; 1992 Nov; 19(4):747-59. PubMed ID: 1441029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
    Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma.
    McCaffrey JA; Herr HW
    Surg Oncol Clin N Am; 1997 Oct; 6(4):667-81. PubMed ID: 9309087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
    Stöckle M; Meyenburg W; Wellek S; Voges G; Gertenbach U; Thüroff JW; Huber C; Hohenfellner R
    Ann Urol (Paris); 1993; 27(1):51-7. PubMed ID: 7682388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Systemic chemotherapy in advanced bladder cancer. New aspects].
    Jakse G
    Wien Klin Wochenschr; 1987 Jan; 99(2):54-7. PubMed ID: 3564487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
    Pectasides D; Pectasides M; Economopoulos T
    Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR; Nieuwenhuijzen JA; Meinhardt W; Bais EM; Horenblas S
    Eur J Surg Oncol; 2009 Apr; 35(4):352-5. PubMed ID: 18722076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for advanced urothelial cancer.
    Yagoda A
    Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers].
    Takenaka A; Gotoh A; Hara I; Gohji K; Ogawa T; Arakawa S; Matsumoto O; Kamidono S; Hamami G; Itani A
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inductive chemotherapy of bladder cancer. A critical evaluation].
    Debruyne FM
    Urologe A; 1991 Mar; 30(2):81-4. PubMed ID: 2058072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.
    Aparicio AM; Elkhouiery AB; Quinn DI
    Urol Clin North Am; 2005 May; 32(2):217-30, vii. PubMed ID: 15862619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status.
    Walther PJ
    Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.